Seneca valley virus (SVV) cellular receptor targeted oncotherapy
AssigneeMemorial Sloan Kettering Cancer Center
InventorsLinde Miles, John Poirier, Charles Rudin
Life of this patent
Estimating the term…
Abstract
A method for selecting cancer patient for treatment with Seneca Valley Virus (SVV) by determining expression of ANTXR1 in a cancerous tissue in a cancer patient; and designating the cancer patient as a candidate for treatment with SVV if normal levels or elevated levels of ANTXR1 expression is detected in the cancerous tissue. Also a method for treating a cancer patient with SVV is disclosed.
Claims20
A method of treating cancer comprising administering an effective amount of a Seneca Valley Virus (SVV), a SVV mutant, or a SVV variant to a subject identified as having a cancerous tissue with a normal expression level or an elevated expression level of anthrax toxin receptor 1 (ANTXR1) and a decreased expression level of a type I interferon (IFN-1).
Dependencies are inferred from the claim text.